Analysis of tumor samples and circulating tumor DNA (ctDNA) of patients receiving CDK4/6i plus ET have shown loss of RB1 at baseline or with treatment is associated with shorter progression-free survival (PFS), although such alterations appear uncommon, occurring in < 10% of resistant samples [2, 4–6]. The gene discussed is CDK4; the disease is neoplasm.